We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+7.66%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$5.72B
AUM Growth
+$403M
Cap. Flow
+$53M
Cap. Flow %
0.93%
Top 10 Hldgs %
15.98%
Holding
769
New
66
Increased
305
Reduced
281
Closed
46

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$44.4M
2
PG icon
Procter & Gamble
PG
+$30.3M
3
BIDU icon
Baidu
BIDU
+$26.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$22.2M
5
LLY icon
Eli Lilly
LLY
+$22.1M

Sector Composition

Rank Sector Weight
1 Healthcare 27.14%
2 Technology 13.76%
3 Financials 13.55%
4 Consumer Discretionary 9.45%
5 Communication Services 7.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FOLD
201
DELISTED
Amicus Therapeutics
FOLD
$7.28M 0.13%
482,400
-314,500
-39% -$4.16M
IONS icon
202
Ionis Pharmaceuticals
IONS
$9.35B
$7.25M 0.13%
143,000
+33,000
+30% +$1.73M
PANW icon
203
Palo Alto Networks
PANW
$264B
$7.22M 0.13%
300,486
+64,122
+27% +$1.46M
EWC icon
204
iShares MSCI Canada ETF
EWC
$6.04B
$7.19M 0.13%
248,570
+16,500
+7% +$459K
WMB icon
205
Williams Companies
WMB
$90.5B
$7.18M 0.13%
239,261
+177,665
+288% +$5.41M
PSX icon
206
Phillips 66
PSX
$82.9B
$6.98M 0.12%
76,166
+1,786
+2% +$151K
PTLA
207
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$6.94M 0.12%
128,500
-2,000
-2% -$117K
IMMU
208
DELISTED
Immunomedics Inc
IMMU
$6.91M 0.12%
494,500
-55,500
-10% -$553K
TFCFA
209
DELISTED
Twenty-First Century Fox, Inc. Class A
TFCFA
$6.89M 0.12%
261,190
+113,484
+77% +$3.13M
PBYI icon
210
Puma Biotechnology
PBYI
$406M
$6.89M 0.12%
57,500
+8,500
+17% +$791K
TD icon
211
Toronto Dominion Bank
TD
$198B
$6.87M 0.12%
122,315
-10,810
-8% -$568K
IYR icon
212
iShares US Real Estate ETF
IYR
$4.59B
$6.85M 0.12%
85,800
+7,700
+10% +$618K
SYK icon
213
Stryker
SYK
$127B
$6.79M 0.12%
47,796
+446
+0.9% +$64K
TWX
214
DELISTED
Time Warner Inc
TWX
$6.75M 0.12%
65,884
-18,561
-22% -$1.88M
APD icon
215
Air Products & Chemicals
APD
$66.3B
$6.72M 0.12%
44,414
-30,237
-41% -$4.43M
QCOM icon
216
Qualcomm
QCOM
$176B
$6.7M 0.12%
129,325
-126,295
-49% -$6.68M
DUK icon
217
Duke Energy
DUK
$102B
$6.64M 0.12%
79,092
+1,093
+1% +$93.6K
KMI icon
218
Kinder Morgan
KMI
$73.1B
$6.62M 0.12%
344,970
-275,920
-44% -$5.38M
OXY icon
219
Occidental Petroleum
OXY
$57B
$6.61M 0.12%
102,860
-4,086
-4% -$249K
RY icon
220
Royal Bank of Canada
RY
$291B
$6.56M 0.11%
85,020
-10,665
-11% -$796K
FE icon
221
FirstEnergy
FE
$28.9B
$6.56M 0.11%
212,854
-11,224
-5% -$353K
PNC icon
222
PNC Financial Services
PNC
$100B
$6.54M 0.11%
48,547
-5,580
-10% -$716K
APC
223
DELISTED
Anadarko Petroleum
APC
$6.52M 0.11%
133,428
+2,619
+2% +$115K
AMT icon
224
American Tower
AMT
$77.7B
$6.42M 0.11%
46,941
+4,739
+11% +$660K
ADP icon
225
Automatic Data Processing
ADP
$100B
$6.37M 0.11%
58,280
+762
+1% +$81.6K

Similar funds

Candriam SCA's Q3 2017 Portfolio in Review

As of Q3 2017, Candriam SCA held 769 positions worth $5.72B, up 7.6% from $5.32B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Candriam SCA's Q3 2017 filing shows 66 new, 305 increased, 281 reduced and 46 closed positions. Its largest new stake was Alaska Air: 139,079 shares worth $10.6M. The largest sale was GE Aerospace, an estimated $30.7M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 26% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q3 2017 buy was Alaska Air: 139,079 shares worth $10.6M.
  • Candriam SCA added most to Microsoft in Q3 2017, an estimated $44.4M increase.
  • Candriam SCA's biggest Q3 2017 reduction was GE Aerospace, cutting an estimated $30.7M.
  • Candriam SCA fully exited Staples Inc in Q3 2017, selling an estimated $26.4M.
  • Candriam SCA's ten largest holdings make up 16% of its $5.72B portfolio in Q3 2017.
  • Candriam SCA opened 66 new positions and closed 46 in Q3 2017.
  • Candriam SCA's portfolio value rose 7.6% quarter-over-quarter to $5.72B.

Based on Candriam SCA's 13F filing for Q3 2017, filed 3 Nov 2017.